State-of-the-art methods and devices for the generation, exposure, and collection of aerosols from heat-not-burn tobacco products

Boué, Stéphanie; Goedertier, Didier; Hoeng, Julia; Kuczaj, Arkadiusz K.; Majeed, Shoaib; Mathis, Carole; May, Anne; Phillips, Blaine; Peitsch, Manuel C.; Radtke, F.; Schlage, Walter K.; Wei, Tan; Vanscheeuwijck, Patrick

doi:10.1177/2397847319897869

Cited by 13 publications

(32 citation statements)

References 136 publications

(219 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, new types of product have emerged in the tobacco market. In particular, products such as e-cigarettes and heat-not-burn (HnB) products are becoming increasing popular owing to their claimed function of being able to reduce or even eliminate toxicity or mutagenicity of cigarette smoke (Chaoying, 2017;Simonavisius et al 2018;Boue et al 2020).…”

Section: Accepted Manuscript Introductionmentioning

confidence: 99%

Modeled Respiratory Tract Deposition of Smoke Aerosol from Conventional Cigarettes, Electronic Cigarettes and Heat-not-burn Products

Cui

Chen

et al. 2021

Aerosol Air Qual. Res.

View full text Add to dashboard Cite

Knowledge of the deposition of inhaled smoke aerosol in the human respiratory tract has great value for risk assessments of the inhalation toxicology of tobacco products. In this study, differential mobility spectrometry (DMS) was used to characterize smoke particles generated from a conventional cigarette, e-cigarette and heat-not-burn product. The aerosol properties obtained by DMS were then applied to a Multiple Path Particle Dosimetry (MPPD) model to predict the deposition of aerosol particles in the human respiratory tract. The DMS results showed that the particle size distribution of aerosol from the three products differed considerably, with a count median diameter of 14.2～25.4 nm, 50.6～55.3 nm and 172～179 nm for the e-cigarette, heatnot-burn product and conventional cigarette, respectively. However, there was no significant difference in the particle number concentration of aerosol from the three products. The MPPD model indicated that the total deposition fraction of aerosol particles from the e-cigarette and heatnot-burn product was higher than that from the conventional cigarette, and deposition of particles from the e-cigarette in the three human airway regions (head airway, tracheobronchial and pulmonary regions) was higher than that from the heat-not-burn product and conventional cigarette; the particle number concentration deposited in the pulmonary region was the highest, comprising more than 60% of total deposition. Lastly, among the lung lobes, the highest number deposition fraction occurred in the right lower lobe. The relationship between deposition fraction and airway generation was relatively similar among the three aerosols, and the highest deposition fraction occurred in the 20 th to 23 rd generation airways. The deposition results showed that smaller particles, such as those from the e-cigarette aerosol, were more easily deposited in the human respiratory tract. Combined with knowledge of the harmful aerosol constituents, these deposition data will provide important information for hazard evaluation of new tobacco products.

show abstract

Section: Accepted Manuscript Introductionmentioning

confidence: 99%

Modeled Respiratory Tract Deposition of Smoke Aerosol from Conventional Cigarettes, Electronic Cigarettes and Heat-not-burn Products

Cui

Chen

et al. 2021

Aerosol Air Qual. Res.

View full text Add to dashboard Cite

show abstract

“…EXtrelut® NT 3 cartridges use a chemically inert, wide-pore, highly pure diatomaceous earth-based solid phase and are commonly used to trap the nicotine present in the gas and particulate phases of nicotine-containing aerosols. 84…”

Section: Offline Methodsmentioning

confidence: 99%

“…Their use for PSD measurement of ENDP aerosols has been described previously. 84 Cascade impactors are the most commonly used instruments for measuring aerosol PSD, and they are a reference method for inhaled pharmaceutical products. 109,110 A cascade impactor uses particle inertia to size fractionate an aerosol.…”

Section: Physical Characterization Of E-vapors-particle Size Distribumentioning

confidence: 99%

“…Test item number, trapping solvent volume, sample collection point, and trapping temperature may all influence the efficiency of trapping a given fraction from a given aerosol. 84,121 In vitro toxicity testing at the ALI ALI exposure systems have been continuously developed since the 1970s, 83 and various commercial or in-house- designed systems are currently applied in a range of research areas. 123 Researchers are increasingly using exposure systems at the ALI to study aerosols such as CS, ENDP aerosols, and e-vapors.…”

Section: Collection Of E-vapor Fractions For In Vitro Toxicity Testinmentioning

confidence: 99%

“…Test item number, trapping solvent volume, sample collection point, and trapping temperature may all influence the efficiency of trapping a given fraction from a given aerosol. 84,121…”

Section: In Vitro Toxicity Testing In Submersed Cell Culturesmentioning

confidence: 99%

See 2 more Smart Citations

State-of-the-art methods and devices for generation, exposure, and collection of aerosols from e-vapor products

Boué

Goedertier

Hoeng

et al. 2020

Toxicology Research and Application

Self Cite

View full text Add to dashboard Cite

E-vapor products (EVP) have become popular alternatives for cigarette smokers who would otherwise continue to smoke. EVP research is challenging and complex, mostly because of the numerous and rapidly evolving technologies and designs as well as the multiplicity of e-liquid flavors and solvents available on the market. There is an urgent need to standardize all stages of EVP assessment, from the production of a reference product to e-vapor generation methods and from physicochemical characterization methods to nonclinical and clinical exposure studies. The objective of this review is to provide a detailed description of selected experimental setups and methods for EVP aerosol generation and collection and exposure systems for their in vitro and in vivo assessment. The focus is on the specificities of the product that constitute challenges and require development of ad hoc assessment frameworks, equipment, and methods. In so doing, this review aims to support further studies, objective evaluation, comparison, and verification of existing evidence, and, ultimately, formulation of standardized methods for testing EVPs.

show abstract

Key challenges for in vitro testing of tobacco products for regulatory applications: Recommendations for dosimetry

Miller-Holt¹,

Behrsing

Crooks

et al. 2022

Drug Testing and Analysis

View full text Add to dashboard Cite

The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to develop recommendations for optimal scientific and technical approaches for conducting in vitro assays to assess potential toxicity within and across tobacco and various next‐generation products (NGPs) including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDSs). This publication was developed by a working group of the workshop members in conjunction with the sixth workshop in that series entitled “Dosimetry for conducting in vitro evaluations” and focuses on aerosol dosimetry for aerosol exposure to combustible cigarettes, HTP, and ENDS aerosolized tobacco products and summarizes the key challenges as well as documenting areas for future research.

show abstract

State-of-the-art methods and devices for the generation, exposure, and collection of aerosols from heat-not-burn tobacco products

Cited by 13 publications

References 136 publications

Modeled Respiratory Tract Deposition of Smoke Aerosol from Conventional Cigarettes, Electronic Cigarettes and Heat-not-burn Products

Modeled Respiratory Tract Deposition of Smoke Aerosol from Conventional Cigarettes, Electronic Cigarettes and Heat-not-burn Products

State-of-the-art methods and devices for generation, exposure, and collection of aerosols from e-vapor products

Key challenges for in vitro testing of tobacco products for regulatory applications: Recommendations for dosimetry

Contact Info

Product

Resources

About